Study finds certain diabetes drugs may cause bone fractures
NEW YORK A certain class of diabetes drugs may put patients at higher risk of bone fractures, according to a study published in the online edition of the journal PLoS Medicine.
Researchers at the London School of Hygiene and Tropical Medicine, in the United Kingdom, used data from a database of more than 6 million British patients, using data from 1,819 patients aged 40 and older who had experienced a bone fracture while taking at least one drug called a thiazolidinedione.
Taking age and the resulting higher risk of fractures into account, the researchers found that patients had fractures at 1.43 times the rate while taking the drugs as when they didn’t take them. Among patients taking the drugs for four years or more, the rate was twofold. Though the study’s findings suggest an association between the drugs and higher risk of fractures, the researchers cautioned against jumping to conclusions based on them.
“These findings do not prove that thiazolidinediones cause fractures because, despite the self-controlled case-series design of this study, it remains possible that the people who have fractures share some unknown characteristic that affects their chances of breaking a bone,” the researchers wrote.
Thiazolidinediones, also known as glitazones include drugs such as GlaxoSmithKline’s Avandia (rosiglitazone) and Takeda Pharmaceuticals’ Actos (pioglitazone), both of which were included in the study.
Clinical trial results conclude Novartis’ MS drug yields ‘significant’ results
BASEL, Switzerland Patients taking an investigational drug for multiple sclerosis experienced “significant” reductions in relapses and disability progression, according to results of a late-stage clinical trial released Wednesday.
Novartis said initial results of a phase 3 study of the oral MS drug FTY720 (fingolimod) reduced relapse rates by 54% to 60%, compared to placebo, and reduced disability progression by 30% to 32%.
The company said the reduction in relapses was greater than in patients taking interferon beta-1a, a standard of care. A biologic, interferon beta-1a is marketed in various forms under such brand names as Biogen Idec’s Avonex, Merck KGaA’s Rebif and Bayer HealthCare’s Betaseron.
“We are proud to have reached this critical milestone in the development of FTY720, a novel oral therapy that has the potential to transform the treatment of this ultimately disabling disease,” Novartis Pharma global head of development Trevor Mundel said in a statement.
Study finds diabetes most prevalent in southern United States
NEW YORK Diabetes prevalence is highest in the Southern and Appalachian states, and lowest in the Midwest and the Northeast of America, a new study found.
Researchers writing in BioMed Central’s open access journal Population Health Metrics used two public data sources to investigate the prevalence of diagnosed and undiagnosed diabetes mellitus at the state level.
Goodarz Danaei, from the Harvard School of Public Health in Boston, worked with a team of researchers to combine the data from the National Health and Nutrition Examination Survey and the Behavioral Risk Factor Surveillance System.
“Diabetes mellitus is the sixth leading cause of death in the United States, accounting for approximately 70,000 annual deaths,” Danaei said. “To our knowledge, this is the first study to estimate what the true level of diabetes disease is in every state and how the different states perform in terms of diagnosed versus undiagnosed diabetes.”
Age-standardized diabetes prevalence was highest in Mississippi, West Virginia, Louisiana, Texas, South Carolina, Alabama and Georgia, ranging from 15.8% to 16.6% for men and 12.4% to 14.8% for women. The lowest prevalences were found in Vermont, Minnesota, Montana, and Colorado, just 7% for women in the Northeast and some Western states. These results currently provide the only estimates of total diabetes and undiagnosed diabetes in U.S. states.
According to Danaei, “States like Mississippi and Alabama with the highest estimated diabetes prevalence in our analysis also have the highest levels of blood pressure and cardiovascular disease risk. This concentration of cardiovascular risks and diabetes points to the need for lifestyle and health care interventions in these states.”
The researchers hope their figures will provide motivation, guidance, and benchmarks for designing, implementing, and evaluating diabetes prevention and state level control programs at the state level.